BR112021002281A2 - pro-adm para prognosticar o risco de uma condição médica requerendo hospitalização em pacientes com sintomas de doença infecciosa - Google Patents

pro-adm para prognosticar o risco de uma condição médica requerendo hospitalização em pacientes com sintomas de doença infecciosa Download PDF

Info

Publication number
BR112021002281A2
BR112021002281A2 BR112021002281-3A BR112021002281A BR112021002281A2 BR 112021002281 A2 BR112021002281 A2 BR 112021002281A2 BR 112021002281 A BR112021002281 A BR 112021002281A BR 112021002281 A2 BR112021002281 A2 BR 112021002281A2
Authority
BR
Brazil
Prior art keywords
patient
proadm
level
sample
fragment
Prior art date
Application number
BR112021002281-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Darius WILSON
Jesús Francisco Bermejo Martin
Luis Garcia Ortiz
Carmen Herrero Rodriguez
Original Assignee
B.R.A.H.M.S Gmbh
Instituto De Investigación Biomédica De Salamanca
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by B.R.A.H.M.S Gmbh, Instituto De Investigación Biomédica De Salamanca filed Critical B.R.A.H.M.S Gmbh
Publication of BR112021002281A2 publication Critical patent/BR112021002281A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BR112021002281-3A 2018-08-08 2019-08-08 pro-adm para prognosticar o risco de uma condição médica requerendo hospitalização em pacientes com sintomas de doença infecciosa BR112021002281A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18188098.0 2018-08-08
EP18188098 2018-08-08
EP18200907.6 2018-10-17
EP18200907.6A EP3608673A1 (en) 2018-08-08 2018-10-17 Pro-adm for prognosing the risk of a medical condition requiring hospitalization in patients with symptoms of infectious disease
PCT/EP2019/071334 WO2020030745A1 (en) 2018-08-08 2019-08-08 Pro-adm for prognosing the risk of a medical condition requiring hospitalization in patients with symptoms of infectious disease

Publications (1)

Publication Number Publication Date
BR112021002281A2 true BR112021002281A2 (pt) 2021-05-04

Family

ID=63207559

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021002281-3A BR112021002281A2 (pt) 2018-08-08 2019-08-08 pro-adm para prognosticar o risco de uma condição médica requerendo hospitalização em pacientes com sintomas de doença infecciosa

Country Status (7)

Country Link
US (1) US20210293830A1 (https=)
EP (2) EP3608673A1 (https=)
JP (2) JP7402858B2 (https=)
CN (1) CN113056675A (https=)
BR (1) BR112021002281A2 (https=)
CA (1) CA3108835A1 (https=)
WO (1) WO2020030745A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021238591A1 (en) * 2020-03-16 2022-11-17 Adrenomed Ag Pro-Adrenomedullin or fragment thereof in patients infected with Corona virus and treatments with binder against adrenomedullin
WO2021204770A1 (en) * 2020-04-06 2021-10-14 B.R.A.H.M.S Gmbh Pro-adrenomedullin for prognosing disease progression in severe acute respiratory syndrome (sars)
CN116525105B (zh) * 2023-06-29 2023-10-03 中国人民解放军总医院 一种心源性休克预后预测预警系统、设备及可存储介质

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2570703B1 (fr) 1984-09-26 1988-07-08 Commissariat Energie Atomique Complexes macropolycycliques de terres rares et application a titre de marqueurs fluorescents
US4882733A (en) 1987-03-13 1989-11-21 Ford Aerospace Corporation Method and apparatus for combining encoding and modulation
FR2664699B1 (fr) 1990-07-13 1995-08-18 Cis Bio Int Procede d'amplification du signal d'emission d'un compose luminescent.
DE10316583A1 (de) * 2003-04-10 2004-10-28 B.R.A.H.M.S Aktiengesellschaft Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung
ES2300681T3 (es) * 2004-07-22 2008-06-16 Brahms Aktiengesellschaft Procedimiento para el diagnostico y tratamiento de pacientes criticos con endotelina, agonistas de endotelina y antagonistas de adrenomedulina.
CN102203616A (zh) * 2008-10-07 2011-09-28 B.R.A.H.M.S有限公司 用于预测初次不利事件的生物标志物
EP2438447B1 (en) 2009-06-05 2015-02-18 B.R.A.H.M.S GmbH Detection of bacterial infections in subjects suffering from dyspnea.
EP2635904A1 (en) * 2010-11-01 2013-09-11 B.R.A.H.M.S GmbH Prognosis and risk assessment of patients with non-specific complaints
HRP20170427T1 (hr) * 2011-11-16 2017-06-16 Sphingotec Gmbh Testovi na adrenomedulin i postupci određivanja zrelog adrenomedulina
JP6944449B2 (ja) * 2015-11-27 2021-10-06 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング 対象の細胞外液量状態のマーカーとしてのＭＲ−ｐｒｏＡＤＭ
RU2019103403A (ru) * 2016-07-08 2020-08-10 Сфинготек Гмбх Адреномедуллин для оценки застоя у индивидуума с острой сердечной недостаточностью
US20190178897A1 (en) * 2016-08-09 2019-06-13 B.R.A.H.M.S Gmbh Histones and/or proadm as markers indicating organ dysfunction
EP3497451B1 (en) * 2016-08-09 2025-06-18 B.R.A.H.M.S GmbH Histones and/or proadm as markers indicating an adverse event

Also Published As

Publication number Publication date
CA3108835A1 (en) 2020-02-13
EP3833979A1 (en) 2021-06-16
EP3608673A1 (en) 2020-02-12
JP2024023615A (ja) 2024-02-21
US20210293830A1 (en) 2021-09-23
CN113056675A (zh) 2021-06-29
JP7402858B2 (ja) 2023-12-21
WO2020030745A1 (en) 2020-02-13
JP2021534385A (ja) 2021-12-09

Similar Documents

Publication Publication Date Title
AU2021251382B2 (en) Pro-adrenomedullin for prognosing disease progression in severe acute respiratory syndrome (SARS)
JP2024023615A (ja) 感染性疾患の症状を有する患者において入院を必要とする病状のリスクを予測するためのｐｒｏ－ａｄｍ
JP2023111913A (ja) ｐｒｏ－ＡＤＭに基づく抗生物質療法の指導
JP2024091650A (ja) 多発外傷患者の外傷関連合併症の予後診断のためのｐｒｏ－ａｄｍ
US20240393352A1 (en) Antibiotic therapy guidance based on procalcitonin in patients with comorbidities
CN111094981B (zh) Pct和pro-adm作为监测抗生素治疗的标记物
BR112020004138A2 (pt) pro-adm como marcador de monitoramento terapêutico para pacientes doentes em estado crítico
RU2820944C2 (ru) Проадм для прогнозирования риска состояния, требующего госпитализации, у пациентов с симптомами инфекционного заболевания
US20260056215A1 (en) Pro-ADM for Prognosis of Trauma-Related Complications in Polytrauma
RU2782305C2 (ru) Про-адм в качестве маркера мониторинга терапии для критически больных пациентов
HK40030378A (zh) 基於pro-adm的抗生素疗法指导

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]